A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.

Saved in:
Bibliographic Details
Title: A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Authors: Huang AC; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. alexander.huang@uphs.upenn.edu.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. alexander.huang@uphs.upenn.edu.; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA. alexander.huang@uphs.upenn.edu.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. alexander.huang@uphs.upenn.edu., Orlowski RJ; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Merck & Co., Inc., Kenilworth, NJ, USA., Xu X; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Mick R; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., George SM; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Bristol-Myers Squibb, Lawrenceville, NJ, USA., Yan PK; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Manne S; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Kraya AA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wubbenhorst B; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Dorfman L; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., D'Andrea K; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wenz BM; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Liu S; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Chilukuri L; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Kozlov A; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Carberry M; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Giles L; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Kier MW; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Quagliarello F; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Stem Cell Technologies, Vancouver, British Columbia, Canada., McGettigan S; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Kreider K; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Annamalai L; Merck Research Laboratories, Kenilworth, NJ, USA., Zhao Q; Merck Research Laboratories, Kenilworth, NJ, USA., Mogg R; Merck Research Laboratories, Kenilworth, NJ, USA.; Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA., Xu W; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Blumenschein WM; Merck Research Laboratories, Kenilworth, NJ, USA., Yearley JH; Merck Research Laboratories, Kenilworth, NJ, USA., Linette GP; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Amaravadi RK; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Schuchter LM; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Herati RS; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Bengsch B; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, University Medical Center Freiburg, Freiburg, Germany., Nathanson KL; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Farwell MD; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Karakousis GC; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wherry EJ; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.; Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu.; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. wherry@pennmedicine.upenn.edu., Mitchell TC; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tara.mitchell@uphs.upenn.edu.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tara.mitchell@uphs.upenn.edu.
Source: Nature medicine [Nat Med] 2019 Mar; Vol. 25 (3), pp. 454-461. Date of Electronic Publication: 2019 Feb 25.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-019-0357-y